Amgen goes all in on injectable obesity drug as it scraps early-stage pill

Amgen has decided to halt the development of an early-stage obesity pill, shifting its focus to a more promising injectable drug, MariTide, currently in Phase 2 trials. This decision comes as MariTide shows potential to compete with established obesity treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The company is optimistic about MariTide's ongoing trials and is preparing for extensive Phase 3 studies on obesity and related conditions, while also expanding manufacturing capabilities to meet future demand.